330 related articles for article (PubMed ID: 16884450)
21. Review: Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence.
Chan J; Sweeting M
J Psychopharmacol; 2007 Aug; 21(6):657-64. PubMed ID: 17092976
[TBL] [Abstract][Full Text] [Related]
22. Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia.
Vohora D
Curr Opin Investig Drugs; 2007 Jul; 8(7):531-8. PubMed ID: 17659473
[TBL] [Abstract][Full Text] [Related]
23. Cognitive dysfunctions in medicated and unmedicated patients with recent-onset schizophrenia.
Daban C; Amado I; Bourdel MC; Loo H; Olié JP; Poirier MF; Krebs MO
J Psychiatr Res; 2005 Jul; 39(4):391-8. PubMed ID: 15804389
[TBL] [Abstract][Full Text] [Related]
24. [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review].
Khaldi S; Kornreich C; Choubani Z; Gourevitch R
Encephale; 2008 Dec; 34(6):618-24. PubMed ID: 19081460
[TBL] [Abstract][Full Text] [Related]
25. The effects of clozapine on neurocognition: an overview.
Goldberg TE; Weinberger DR
J Clin Psychiatry; 1994 Sep; 55 Suppl B():88-90. PubMed ID: 7525543
[TBL] [Abstract][Full Text] [Related]
26. Facilitating compliance with antipsychotic medication.
Marder SR
J Clin Psychiatry; 1998; 59 Suppl 3():21-5. PubMed ID: 9541334
[TBL] [Abstract][Full Text] [Related]
27. Sexual dysfunction in schizophrenia: focus on recent evidence.
Baggaley M
Hum Psychopharmacol; 2008 Apr; 23(3):201-9. PubMed ID: 18338766
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the serotonin transporter in lymphocytes and platelets of schizophrenia patients treated with atypical or typical antipsychotics compared to healthy individuals.
Barkan T; Peled A; Modai I; Weizman A; Rehavi M
Eur Neuropsychopharmacol; 2006 Aug; 16(6):429-36. PubMed ID: 16431091
[TBL] [Abstract][Full Text] [Related]
29. Cognitive effects of conventional and atypical antipsychotics in schizophrenia.
Sharma T
Br J Psychiatry Suppl; 1999; (38):44-51. PubMed ID: 10884899
[No Abstract] [Full Text] [Related]
30. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
Meltzer HY; Huang M
Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
[TBL] [Abstract][Full Text] [Related]
31. Spatial working memory and problem solving in schizophrenia: the effect of symptom stabilization with atypical antipsychotic medication.
Snyder PJ; Jackson CE; Piskulic D; Olver J; Norman T; Maruff P
Psychiatry Res; 2008 Sep; 160(3):316-26. PubMed ID: 18579217
[TBL] [Abstract][Full Text] [Related]
32. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction.
Kawai N; Yamakawa Y; Baba A; Nemoto K; Tachikawa H; Hori T; Asada T; Iidaka T
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1009-14. PubMed ID: 16644082
[TBL] [Abstract][Full Text] [Related]
33. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
34. Effects of second generation antipsychotics on leptin and ghrelin.
Esen-Danaci A; Sarandöl A; Taneli F; Yurtsever F; Ozlen N
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1434-8. PubMed ID: 18579280
[TBL] [Abstract][Full Text] [Related]
35. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
Burton S
J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
[TBL] [Abstract][Full Text] [Related]
36. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
Piskulić D; Olver JS; Maruff P; Norman TR
Hum Psychopharmacol; 2009 Aug; 24(6):437-46. PubMed ID: 19637398
[TBL] [Abstract][Full Text] [Related]
37. Effects of antipsychotic medications on quality of life and psychosocial functioning in patients with early-stage schizophrenia: 1-year follow-up naturalistic study.
Guo X; Zhang Z; Zhai J; Fang M; Hu M; Wu R; Liu Z; Zhao J;
Compr Psychiatry; 2012 Oct; 53(7):1006-12. PubMed ID: 22516246
[TBL] [Abstract][Full Text] [Related]
38. Do atypical antipsychotics really enhance smoking reduction more than typical ones?: the effects of antipsychotics on smoking reduction in patients with schizophrenia.
Wu BJ; Chen HK; Lee SM
J Clin Psychopharmacol; 2013 Jun; 33(3):319-28. PubMed ID: 23609378
[TBL] [Abstract][Full Text] [Related]
39. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis.
Jann MW
Pharmacotherapy; 2004 Dec; 24(12):1759-83. PubMed ID: 15585443
[TBL] [Abstract][Full Text] [Related]
40. [Pharmacology of second-generation antipsychotics: a validity of the serotonin-dopamine hypothesis].
Kuroki T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Oct; 24(5):257-64. PubMed ID: 15658501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
